Literature DB >> 15040937

Active and passive immunization against Clostridium difficile diarrhea and colitis.

Paul J Giannasca1, Michel Warny.   

Abstract

Clostridium difficile, a gram-positive bacterium, is the major cause of hospital-acquired infectious diarrhea and colitis in industrialized nations. C. difficile colonization results from antibiotic administration and subsequent loss of protection provided by intestinal flora. C. difficile induced-colitis is caused by the release of two exotoxins, toxin A and B. Host factors including advanced age, pre-existing severe illness and weakened immune defenses predispose individuals to symptomatic infection. The generation of antibody responses to toxin A through natural exposure is associated with protection from disease. In addition, an inability to acquire immunity to toxin A puts individuals at risk for recurrent and/or severe disease. Immunological approaches for the management of this disease are being developed which could reduce the reliance on antibiotics for treatment and allow for re-establishment of the natural barrier provided by an intact commensal flora. An active vaccine and various immunotherapeutic strategies under evaluation may prove to be effective against severe or relapsing C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15040937     DOI: 10.1016/j.vaccine.2003.11.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.

Authors:  Rory N Pruitt; Nicole M Chumbler; Stacey A Rutherford; Melissa A Farrow; David B Friedman; Ben Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

3.  Protecting against Clostridium difficile illness.

Authors:  Erica Weir; Ken Flegel
Journal:  CMAJ       Date:  2005-04-26       Impact factor: 8.262

4.  Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface.

Authors:  Heather K Kroh; Ramyavardhanee Chandrasekaran; Kim Rosenthal; Rob Woods; Xiaofang Jin; Melanie D Ohi; Andrew C Nyborg; G Jonah Rainey; Paul Warrener; Benjamin W Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2017-07-13       Impact factor: 5.157

5.  Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Authors:  Patima Permpoonpattana; Huynh A Hong; Jutarop Phetcharaburanin; Jen-Min Huang; Jenny Cook; Neil F Fairweather; Simon M Cutting
Journal:  Infect Immun       Date:  2011-04-11       Impact factor: 3.441

Review 6.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

7.  Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.

Authors:  Sergey S Seregin; Yasser A Aldhamen; David P W Rastall; Sarah Godbehere; Andrea Amalfitano
Journal:  Vaccine       Date:  2011-12-23       Impact factor: 3.641

8.  Treatment of Recurrent Clostridium difficile Diarrhea.

Authors:  Elizabeth S Huebner; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

9.  Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.

Authors:  Ke Jin; Shixia Wang; Chunhua Zhang; Yanling Xiao; Shan Lu; Zuhu Huang
Journal:  Hum Vaccin Immunother       Date:  2012-11-10       Impact factor: 3.452

Review 10.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.